Effect of Polyplex Morphology on Cellular Uptake, Intracellular Trafficking, and Transgene Expression
Source abstract
Abstract
Nanoparticle morphology has been shown to affect cellular uptake, but there are few studies investigating the impact of particle shape on biologic drug delivery. Recently, our group synthesized a series of N-(2-hydroxypropyl) methacrylamide (HPMA)-oligolysine brush polymers for nucleic acid delivery that varied in oligolysine peptide length and polymer molecular weight. Interestingly, a 50% longer peptide (K15) transfected very poorly compared to the optimized polymer comprised of K10 peptide despite similar chemical composition and molecular weight. We hypothesized that differences in particle morphology contributed to the differences in plasmid DNA delivery. We found that particles formed with plasmid DNA and a polymer with the longer oligolysine peptide (pHK15) had larger aspect ratios than particles formed with optimized polymer (pHK10). Even though both formulations showed similar percentages of cellular association, particles of a higher aspect ratio were internalized to a lesser extent. Furthermore, the rod-like particles accumulated more in endosomal/lysosomal compartments, leading to delayed nuclear delivery. Other parameters, such as particle surface charge, unpackaging ability, uptake mechanism, intracellular trafficking, and the presence of heparan sulfate proteoglycans did not significantly differ between the two polymer formulations. These results indicate that, for this system, polyplex morphology primarily impacts nucleic acid delivery efficiency through differences in cellular internalization rates.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Bioengineering and Molecular Engineering & Sciences Institute, University of Washington, 3720 15th Avenue NE, Box 355061, Seattle, Washington 98195, United States
Funding
National Science Foundation · National Institute of Neurological Disorders and Stroke
References (41)
Show source-provided references
1. Sahay G. · J. Controlled Release · 2010 · 145 · 18210.1016/j.jconrel.2010.01.036 ↗
2. Duncan R. · Mol. Pharmaceutics · 2012 · 9 · 238010.1021/mp300293n ↗
3. Barua S. · Proc. Natl. Acad. Sci. U. S. A. · 2013 · 110 · 327010.1073/pnas.1216893110 ↗
4. Gratton S. E. A. · Proc. Natl. Acad. Sci. U. S. A. · 2008 · 105 · 1161310.1073/pnas.0801763105 ↗
5. Herd H. · ACS Nano · 2013 · 7 · 196110.1021/nn304439f ↗
6. Huang X. · Biomaterials · 2010 · 31 · 43810.1016/j.biomaterials.2009.09.060 ↗
7. Chithrani B. D. · Nano Lett. · 2006 · 6 · 66210.1021/nl052396o ↗
8. Chithrani B. D. · Nano Lett. · 2007 · 7 · 154210.1021/nl070363y ↗
9. Chaudhuri P. · ACS Nano · 2010 · 4 · 57410.1021/nn901465h ↗
10. Johnson R. N. · J. Controlled Release · 2011 · 155 · 30310.1016/j.jconrel.2011.07.009 ↗
11. Nayvelt I. · Biomacromolecules · 2007 · 8 · 47710.1021/bm0605863 ↗
12. Mann A. · J. Controlled Release · 2008 · 125 · 25210.1016/j.jconrel.2007.10.019 ↗
13. Yoo J.-W. · Macromol. Rapid Commun. · 2010 · 31 · 14210.1002/marc.200900592 ↗
14. Männistö M. · J. Controlled Release · 2002 · 83 · 16910.1016/S0168-3659(02)00178-5 ↗
15. Ruponen M. · J. Biol. Chem. · 2001 · 276 · 3387510.1074/jbc.M011553200 ↗
16. Mislick K. A. · Proc. Natl. Acad. Sci. U. S. A. · 2005 · 93 · 1234910.1073/pnas.93.22.12349 ↗
17. Ziraksaz Z. · Eur. J. Pharm. Sci. · 2013 · 48 · 5510.1016/j.ejps.2012.10.016 ↗
18. Naik R. J. · J. Biol. Chem. · 2011 · 286 · 1898210.1074/jbc.M111.227793 ↗
19. Åmand H. L. · Biochim. Biophys. Acta · 2012 · 1818 · 266910.1016/j.bbamem.2012.06.006 ↗
20. McLendon P. M. · Mol. Pharmaceutics · 2010 · 7 · 73810.1021/mp900282e ↗
21. Reilly M. J. · Mol. Pharmaceutics · 2012 · 9 · 128010.1021/mp200583d ↗
22. Fichter K. M. · ACS Nano · 2013 · 7 · 34710.1021/nn304218q ↗
23. Vercauteren D. · J. Controlled Release · 2012 · 161 · 56610.1016/j.jconrel.2012.05.020 ↗
24. Wang L. H. · J. Cell Biol. · 1993 · 123 · 110710.1083/jcb.123.5.1107 ↗
25. Akiyama T. · J. Biol. Chem. · 1987 · 262 · 559210.1016/S0021-9258(18)45614-1 ↗
26. Aoki T. · Exp. Cell Res. · 1999 · 253 · 62910.1006/excr.1999.4652 ↗
27. Hewlett L. J. · J. Cell Biol. · 1994 · 124 · 68910.1083/jcb.124.5.689 ↗
28. Shi J. · Biomacromolecules · 2013 · 130520073834008
29. Payne C. K. · Traffic · 2007 · 8 · 38910.1111/j.1600-0854.2007.00540.x ↗
30. Chen H. H. · Mol. Ther. · 2008 · 16 · 32410.1038/sj.mt.6300392 ↗
31. Oh Y.-K. · Gene Ther. · 2002 · 9 · 162710.1038/sj.gt.3301735 ↗
32. Hartig R. · Biol. Cell · 1998 · 90 · 40710.1111/j.1768-322X.1998.tb01050.x ↗
33. Staufenbiel M. · Exp. Cell Res. · 1982 · 138 · 20710.1016/0014-4827(82)90107-0 ↗
34. Shi J. · Mol. Pharmaceutics · 2013 · 10 · 214510.1021/mp300651q ↗
35. Grigsby C. L. · J. R. Soc., Interface · 2010 · 7 · S67
36. Kim A. J. · Biophys. Rev. · 2012 · 1
37. de Bruin K. · Mol. Ther. · 2007 · 15 · 129710.1038/sj.mt.6300176 ↗
38. Suh J. · Int. J. Nanomed. · 2007 · 2 · 73510.2217/17435889.2.5.735 ↗
39. Lai S. K. · J. Controlled Release · 2008 · 125 · 10710.1016/j.jconrel.2007.10.015 ↗
40. Kim A. J. · J. Controlled Release · 2012 · 158 · 10210.1016/j.jconrel.2011.10.031 ↗
41. Lai S. K. · Methods Mol. Biol. · 2008 · 434 · 81